Do you want to read an article? Please log in or register.
Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial
Further Publications
Related content
Gastroesophageal Reflux Disease (GERD)
Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease
Eur J Gastroenterol Hepatol.
Wilkinson J, Wade A, Thomas SJ, Jenner B, Hodgkinson V, Coyle C
doi: 10.1097/MEG.
Hepatology
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial
Lancet Gastroenterol Hepatol.
Pose E, Napoleone L, Amin A, Campion D, Jimenez C, Piano S, Roux O, Uschner FE, de Wit K, Zaccherini G, Alessandria C, Angeli P, Bernardi M, Beuers U, Caraceni P, Durand F, Mookerjee RP, Trebicka J, Vargas V, Andrade RJ, Carol M, Pich J, Ferrero J, Domenech G, Llopis M, Torres F, Kamath PS, Abraldes JG, Solà E, Ginès P
doi: 10.1016/S2468-1253(19)30320-6.
RECOMMENDED
Irritable Bowel Syndrome (IBS) and Chronic Constipation
Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
doi: 10.1016/S2468-1253(20)30056-X.
RECOMMENDED
Celiac Disease
Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study
Lancet Gastroenterol Hepatol.
Lähdeaho ML, Scheinin M, Vuotikka P, Taavela J, Popp A, Laukkarinen J, Koffert J, Koivurova OP, Pesu M, Kivelä L, Lovró Z, Keisala J, Isola J, Parnes JR, Leon F, Mäki M
doi: 10.1016/
Hepatitis
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Lancet.
Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE
doi: 10.1016/S0140-6736(19)32517-6.
RECOMMENDED
Celiac Disease
Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study
Lancet Gastroenterol Hepatol.
Cellier C, Bouma G, van Gils T, Khater S, Malamut G, Crespo L, Collin P, Green PHR, Crowe SE, Tsuji W, Butz E, Cerf-Bensussan N, Macintyre E, Parnes JR, Leon F, Hermine O, Mulder CJ, RCD-II Study Group Investigators.
doi: 10.1016/
Further Publications
Curcuma longa Linn Versus Omeprazole in Treatment of Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Trial
J Gastroenterol Hepatol
Yongwatana K, Harinwan K, Chirapongsathorn S, Opuchar K, Sanpajit T, Piyanirun W, Puttapitakpong C
doi: 10.1111/jgh.15705
Inflammatory Bowel Disease
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
Lancet
Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L
doi: 10.1016/S0140-6736(21)00666-8
Hepatology
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Lancet Gastroenterol Hepatol
Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, Xu A, Chen X, Zhou C, Ren Z, Yang L, Xu L, Bai Y, Chen L, Li J, Pan H, Cao B, Fang W, Wu W, Wang G, Cheng Y, Yu Z, Zhu X, Jiang D, Lu Y, Wang H, Xu J, Bai L, Liu Y, Lin H, Wu C, Zhang Y, Yan P, Jin C, Zou J
doi: 10.1016/S2468-1253(21)00109-6